Nuvilex (NASDAQ:PMCB – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.48), FiscalAI reports.
Nuvilex Trading Down 12.9%
PMCB opened at $0.39 on Tuesday. The business’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.68. The company has a market cap of $4.21 million, a P/E ratio of -0.13 and a beta of 0.66. Nuvilex has a 12 month low of $0.35 and a 12 month high of $1.51.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings downgraded shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Nuvilex Company Profile
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.
Featured Articles
- Five stocks we like better than Nuvilex
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
